AMRI, a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life, has secured a seven-year contract from the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), USA.
AMRI’s activities under the contract will focus on the development and manufacture of active pharmaceutical ingredients (API) and drug product for Phase I clinical studies. The bulk of AMRI’s work will occur at the company’s Albany, New York, facilities.
Other programs where AMRI is contracted to provide services to NIH-funded researchers include the company’s selection as a Dedicated Chemical Biology Consortium (CBC) Center for the NCI Experimental Therapeutics (NExT) Program, the National Center for Advancing Translational Sciences (NCATS) and the Blueprint Neurotherapeutics Network.
AMRI, a global contract research and manufacturing organization, has locations in North America, Europe and Asia. AMRI’s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in discovery, development, analytical services; API manufacturing; and drug product.
The National Institute of Allergy and Infectious Diseases (NIAID) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID’s mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.